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We have studied the expression and the localization of the cellular proteins CBP/p300 and RBP-Jk in in vitro EBV-infected
human B lymphocytes in relation to the EBNA-2 and EBNA-5 proteins. We found that the level of CBP/p300 was elevated
drastically by EBV infection and also after activation by CD40 ligation. Thus the increase in CBP/p300 expression in the
EBV-infected cells is related to the virus-induced activation and proliferation of the cells. EBNA-2 and RBP-Jk colocalized in
the nucleoplasm, which is in accordance with their functional interaction. We confirmed earlier reports about the presence
and colocalization of EBNA-5 and CBP in the nuclear POD bodies. On the other hand, neither EBNA-2 nor p300 was detected
in the PODs. The expression of these two proteins overlapped in some distinct dots of the nucleoplasm. Taken together, the
different patterns of CBP and p300 expression and their different localization in relation to the PML bodies and two
EBV-encoded proteins in the B cells may provide some clue to their distinct functional roles. © 2001 Academic Press
Key Words: EBV, EBNA-5, EBNA-2, RBP-Jk, CBP, p300, PML bodies.
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aINTRODUCTION
Resting B lymphocytes can be immortalized to gener-
ate permanently growing cultures by Epstein–Barr virus
(EBV) infection. The resulting lymphoblastoid cell lines
(LCLs) express nine virally encoded proteins. Among
these, six are located in the nucleus (EBNA-1 to -6) and
three are membrane proteins (LMP-1, -2A, -2B) (reviewed
by Rickinson and Kieff, 1996). EBNA-2 and EBNA-5 (also
named EBNA-LP) are the earliest virally encoded pro-
teins expressed after infection. They drive the resting B
cells to enter the cell cycle (Sinclair et al., 1994) and thus
initiate the EBV-induced immortalization process.
EBV recombinant-based genetic analysis showed that
EBNA-1, -2, -3, -5, -6, and LMP-1 are essential for B cell
immortalization. EBNA-2 functions as a transactivator
that upregulates both viral and cellular genes, such as
LMP-1, LMP-2A, and LMP-2B, the viral C-promoter
(Woisetschlaeger et al., 1991), and c-myc (Kaiser et al.,
1999). EBNA-2 interacts with DNA through the mediation
of the cellular transcription factors RBP-Jk and PU.1 (Jo-
hannsen et al., 1995; Ling et al., 1993). It also collabo-
rates with the transcriptional coactivators CBP and p300
(Wang et al., 2000).
1 To whom reprint requests should be addressed at present address:
arolinska Institute, Microbiology and Tumor Biology Center, Box 280,
-171 77 Stockholm, Sweden. Fax: 46 8 33 04 98. E-mail:
entaro.bandobashi@mtc.ki.se.
275EBNA-5 is important for EBV-induced B cell transfor-
mation. Recombinant EBV that carried an EBNA-5 mutant
showed a 10-fold-reduced immortalizing capacity (Man-
nick et al., 1991). EBNA-5 enhances the Cp and LMP-1
promoters activating the function of EBNA2 (Harada and
Kieff, 1997; Nitsche et al., 1997). In some LCLs EBNA-5
appears in the PML bodies (Sze´kely et al., 1996), which
also contain pRb (Jiang et al., 1991) and the 70-kDa heat
shock protein (hsp 70) (Sze´kely et al., 1995).
The CREB-binding protein (CBP) and p300 are tran-
scriptional coactivators with histone acetylase activity
(Bannister and Kouzarides, 1996). CBP and p300 have
70% homology. They interact with cellular proteins such
as c-jun and p53 (Bannister et al., 1995; Scolnick et al.,
1997) and with the adenoviral protein E1A and with
EBNA-2 (Arany et al., 1995; Wang et al., 2000). In murine
mbryo fibroblasts, CBP influences the EBNA-2-medi-
ted activation of the c-myc promoter through the inter-
eron responsive PRF element. In this system, p300 has
n opposite, repressor effect (Jayachandra et al., 1999).
In the present work, we have confirmed that in addition
to their nucleoplasmic localization EBNA-5 and CBP are
present in the PML bodies (PODs). In contrast to the
finding on Hep-2 cells (von Mikecz et al., 2000), we did
not detect p300 in the PODs of B cells. EBNA-2 and
RBP-Jk showed almost complete colocalization in the
nucleoplasm. Some large dots in the nucleoplasm were
positive for both EBNA-2 and p300.
0042-6822/01 $35.00
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276 BANDOBASHI ET AL.RESULTS
xpression of CBP and p300 in tonsil-derived B cells
The expression of CBP and p300 proteins was detect-
ble by immunofluorescence in all tonsil-derived B cells.
ome large cells were present in the freshly separated B
ell suspension. These disappeared after 96 h in culture.
n contrast, the majority of cells were blasts after 96 h in
he EBV-infected samples (Figs. 1C and 1G).
CBP staining was confined to the nucleoplasm and
ad a trabecular pattern (Fig. 1A). In addition, several
right dots could be distinguished which, according to
n earlier description, represented PML bodies (LaMorte
t al., 1998). In the small resting B cells, the staining of
300 was weaker than that of CBP (Figs. 1A and 1E).
300 staining showed homogeneously distributed fine
ots. In uninfected control cell cultures at 96 h, both CBP
nd p300 stainings were weak in all cells, but in the CBP
taining brilliant dots could be still seen (Figs. 1D and
H).
Ninety-six hours after infection the majority of cells
ere blast transformed, as indicated by the decon-
ensed chromatin and the large nucleus. Compared to
he small cells, the CBP staining in the nucleoplasm was
ore homogeneous and the number of PML bodies was
igher in the blasts (Fig. 1C). They could be distin-
uished easily against the homogeneously distributed
taining in the background. Compared to the small cells,
300 staining became conspicuously stronger in the
lasts and distinct brilliant dots could be distinguished
Figs. 1F and 1G).
The CBP/p300 levels were assessed by immunoblot-
ing (Fig. 2A). In fresh cells CBP and p300 could be
etected and the amounts of both proteins decreased in
he cultures. In the EBV-infected samples, they also de-
reased after 24 h, but in the 96-h culture their levels
ere considerably increased. Detection by immunofluo-
escence and by immunoblotting showed similar results,
hich are in accordance with the preponderance of
lasts in the 96-h cultures. To clarify whether CBP/p300
nduction is confined to the EBV-infected cells, peripheral
lood B cells were activated for 96 h by exposure to
D40L. In these cultures, the majority of cells were
lasts and the CBP and p300 levels increased consider-
bly (Fig. 2B).
xpression of EBNA-5 and CBP/p300 in EBV-infected
cells
In order to study the spatial relationship between
BNA-5 and CBP/p300, the cells were stained simulta-
eously with the anti-EBNA-5 and the anti-CBP/p300
eagents. In addition to the diffuse staining of the nucle-
plasm, CBP and EBNA-5 appeared in brilliant nuclear
ots (Fig. 3), identified as PML bodies (Fig. 4) (Sze´kely et
l., 1996). All cells in the population were CBP positive
p
bnd in those which expressed EBNA-5 the stainings in
he PML bodies also completely overlapped (Figs. 3A–
C). In the nucleoplasm the CBP and EBNA-5 staining
FIG. 1. Immunofluorescence staining for CBP/p300 in EBV-infected B
cell populations. (A, E) 0 h, (B, F) 24 h, and (C, G) 96 h after EBV
infection. (D, H) Uninfected B cells cultured for 96 h. The population
contained 33 and 68% EBNA2-positive cells in the samples 24 and 96 h
after infection, respectively. Note the enlargement of the cells 96 h after
infection and the difference in the CBP and p300 staining pattern (C, G).
In the small cells the CBP staining in the nucleoplasm is trabecular,
and in the blasts it is more homogeneous. Compared to the small cells,
the intensity of p300 staining is stronger in the blasts. Scale bar, 5 mm.atterns were similar, but the degree of overlap could not
e decided. All cells expressed p300. The PML bodies
277INTRANUCLEAR LOCALIZATION OF CBP/p300, EBNA-2, AND EBNA-5did not stain for p300 and the patterns of EBNA-5 and
p300 in the nucleoplasm differed. Thus the p300 and
EBNA-5 proteins were differently located (Figs. 3D–3F).
Expression of EBNA-2, RBP-Jk, and CBP/p300 in EBV-
infected B cells
The staining of EBNA-2 showed a speckled pattern. It
overlapped considerably with the staining for RBP-Jk but
not with that of CBP (Fig. 5). The stainings for EBNA-2
and p300 overlapped in some dots, which could be
observed only in the 3D microscope (Fig. 6).
Expression of CBP and EBNA-5 in DG75 cells
transfected with EBNA-5
EBNA-5 introduced by transfection into EBV-negative
cells, DG75, was found to be localized in the PML bod-
ies. The culture contained fewer than 5% EBNA-5-posi-
tive cells. In these cells, the staining for CBP and EBNA-5
overlapped completely (Fig. 7). On the other hand, DG75
cells transfected with EBNA-2 failed to show colocaliza-
tion between EBNA-2 and p300. This culture contained
many EBNA-2-positive cells (not shown).
DISCUSSION
Growth transformation of B lymphocytes by EBV in-
volves complex interactions between several virally en-
coded and cellular proteins. Among nine virally encoded
proteins expressed in EBV-immortalized B lymphocytes
EBNA-2 and EBNA-5 are the first to appear after in vitro
infection. Positive cells can be detected after 12 h in the
FIG. 2. (A) Western blot analysis for CBP/p300 in EBV-infected B cell
populations at 0, 24, 48, and 96 h and 7 days of culture of B cells without
and with EBV infection. (B) Western blot analysis for CBP/p300 in B cell
populations stimulated by CD40 ligation at 0 and 96 h of coculture of B
cells with irradiated CD40L-L cells or L cells (control).population (Alfieri et al., 1991). EBNA-2 is a transcrip-
tional activator and acts on specific promoters. The in-duction of LMP-1 expression by EBNA-2 seems to be the
pivotal step for the acquisition of the immortalized phe-
notype. EBNA-2-induced LMP-1 activation requires its
interaction with the cellular proteins RBP-Jk and PU.1,
which bind to DNA (Henkel et al., 1994; Johannsen et al.,
1995). EBNA-5 cooperates in this process through its
enhancing effect (Harada and Kieff, 1997; Nitsche et al.,
1997).
CBP and p300 are related proteins and are usually
mentioned together in discussions concerning their ex-
pression patterns and function. They belong to a family of
transcriptional coactivators. Through interaction with a
variety of cellular and viral proteins they can influence
cell growth, transformation, and development (Goodman
and Smolik, 2000). Their most important activity seems to
be histone acetylation and they contain similar se-
quences within the HAT domains. Depending on the
interacting protein partners, they may have opposite ef-
fects. Interaction of adenovirus-encoded oncoprotein
E1A with CBP/p300 is thought to be critical for the trans-
forming capacity of the virus. Chromosomal transloca-
tions, which affect CBP and p300, have been encoun-
tered in human malignancy (Goodman and Smolik, 2000).
In the present work, we have found that the elevation
of CBP/p300 was induced by EBV infection (Fig. 2A). The
time kinetics suggest that the elevation of CBP/p300 is
not induced directly by EBNA-2 and EBNA-5 because
these EBV-encoded proteins already appeared 24 h after
infection. Indeed we found that CD40 ligation for 96 h
also elevated CBP/p300 expression drastically (Fig. 2B).
Taken together, the data suggested that CBP/p300 in-
duction by EBV is related to the virus-induced activation
and proliferation of the cells.
Recently, it has been shown that the activation of the
LMP-1 promoter by EBNA-2 involves the contribution of
CBP, p300, and PCAF (Wang et al., 2000). In Akata cells
EBNA-2-induced LMP-1 expression was upregulated by
these coactivators. They bind to the acidic domains of
EBNA-2. In 293T cells in which EBNA-2 and p300 were
overexpressed by transfection, about 15% of the EBNA-2
was bound to p300. In our experiments with the EBV-
infected B lymphocytes, some large dots showed colo-
calization of EBNA-2 and p300. However, EBNA-2-trans-
fected DG75 cells failed to show colocalization with
p300. This finding may suggest that cellular and/or viral
factors that are present only in EBV-infected B cells are
involved in the interaction between EBNA-2 and p300.
RBP-Jk colocalized clearly with EBNA-2. RBP-Jk can have
a repressive effect by binding to CBF1 interacting core-
pressor (CIR), which associates with the histone
deacetylase complex (Hsieh et al., 1999). EBNA-2 has
been shown to block this function of RBP-Jk (Hsieh and
Hayward, 1995). The almost complete colocalization of
these two proteins suggests that EBNA-2 sequesters
RBP-Jk. Jayachandra et al. (1999) showed that CBP and
p300 bound to EBNA-2 in cotransfected mouse embryo
g
d
i
u
c
278 BANDOBASHI ET AL.FIG. 3. Double immunofluorescence staining for EBNA-5 and CBP/p300 detection in B cells from a population 7 days after EBV infection. CBP/p300,
green; EBNA-5, red. The population contained about 80% EBNA-5-positive cells. Note the CBP and EBNA-5 staining (A, B) in the large bodies. In
addition, CBP and EBNA-5 (A–C) but not p300 and EBNA-5 (D–F) may colocalize in the nucleoplasm. Scale bar, 5 mm.
FIG. 4. Double immunofluorescence staining for EBNA-5 and PML, CBP, and PML in B cells 7 days after EBV infection. (A–C) EBNA-5, red; PML,
reen. (D–F) CBP, green; PML, red. Note that both EBNA-5 and CBP are expressed in the PML bodies. A complete overlap of CBP and PML is
iscernable, while EBNA-5 and PML may colocalize but not overlap. Scale bar, 5 mm.
FIG. 5. Double immunofluorescence staining for RBP-Jk and EBNA-2; for CBP/p300 and EBNA-2 in a population 7 days after EBV infection. (A–C)
RBP-Jk, red; EBNA-2, green. (D–F) CBP, green; EBNA-2, red. Note the substantial overlap between RBP-Jk and EBNA-2 but no overlap between CBP
and EBNA-2. Scale bar, 5 mm.
FIG. 6. Double immunofluorescence staining for p300 and EBNA-2 at low (A–C) and high (D–F) magnification in a population 7 days after EBV
nfection. P300, green; EBNA-2, red. Note that p300 and EBNA-2 colocalize in some large dots. These images were visualized by the 3D microscope
sing an optical deconvolution algorithm. Scale bar, 5 mm.FIG. 7. Double immunofluorescence staining for CBP and EBNA-5 in DG75 cells with transfected EBNA-5. CBP, green; EBNA-5, red. Note the
olocalization of CBP and EBNA-5 in the PML bodies. Scale bar, 5 mm.
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280 BANDOBASHI ET AL.fibroblasts. However, we could not detect colocalization
of CBP and EBNA-2 in the B cells.
In contrast to the results of von Mikecz et al. (2000),
ho found p300 in a subset of PML bodies in Hep-2
ells, we could not detect p300 in the PODs of B lym-
hocytes. The results may be due to the use of different
ell types in the two sets of experiments. In summary, we
ound a difference in the spatial expression of EBNA-2
nd -5 in infected B lymphocytes. EBNA-5 but not
BNA-2 appeared in the PML bodies. Similarly CBP and
300 differed with regard to their compartmentalization
n the PODs. Their different spatial association with ei-
her EBNA-2 or EBNA-5 and the difference in their ap-
earance in the PODs may provide new clues concern-
ng the distinct functions of CBP and p300. The signifi-
ance of the localization in the PODs for the functions of
he proteins Hsp70, p53, CBP, and EBNA-5 is not yet
nown. Results obtained with influenza nucleoprotein
uggested that PODs are sites for proteasomal degra-
ation of ubiquitinated proteins (Anton et al., 1999). If this
s the case, EBNA-5 may also participate in the regula-
ion of proteasomal degradation.
MATERIAL AND METHODS
ell lines
All cell lines were grown in RPMI culture medium
upplemented with 10% heat-inactivated FCS, 100 U/ml
f penicillin, and 100 U/ml of streptomycin. The cultures
ere split 1:10 every fourth day. Murine L cells (control)
nd L cells transfected with CD40L (CD40L-L cells) were
indly provided by Dr. P. Garrone (Schering Plough, Dar-
illy, France). EBNA-5-transfected DG75 cells (DG75-
BNA-5) and EBNA-2-transfected DG75 cells were kindly
rovided by Dr. Lars Rymo (Gothenburg, Sweden).
ollection and EBV infection of tonsil-derived B cells
Tonsil samples obtained from tonsillectomies were
riefly exposed to ethanol, washed, and minced. The
issue was thereafter passed through a fine metal mesh.
fter two subsequent sheep red blood cell rosettings, the
emaining T cells were depleted with CD2 Dynabeads
Dynal AS, Oslo, Norway). The B cells were incubated
ith B95-8 virus for 1 h, washed, and then cultured in
PMI 10% FCS.
ollection and CD40 stimulation of peripheral blood B
ells
Peripheral blood mononuclear cells were isolated
rom buffy coats of healthy donors by Ficoll–Paque (Phar-
acia, Upsala, Sweden) separation. B cells were sepa-
ated by positive selection using CD19 Dynabeads-450 (Dynal) followed by DETACHaBEAD CD19 (Dynal)
reatment. Purified B cells were cocultured with irradi- oted (15,000 rad) CD40L-L cells or L cells. After 96 h
ulture, the B cells were harvested and then analyzed.
ntibodies
The following antibodies were used: anti-CBP rabbit
olyclonal antibody (A-22; Santa Cruz), anti-p300 rabbit
olyclonal antibody (N-15; Santa Cruz), anti-RBP-Jk rat
onoclonal antibody (T6719; kindly provided by Dr. T.
onjo, Kyoto) (Hamaguchi et al., 1992), anti-PML mouse
onoclonal antibody (PG-M3; Santa Cruz), biotinylated
nti-EBNA-5 mouse monoclonal antibody (JF186) (Finke
t al., 1987), anti-EBNA-2 mouse monoclonal antibody
PE-2; Dakopatts AB), swine anti-rabbit IgG-FITC (Dako-
atts AB), goat anti-mouse IgG-biotin (Southern Biotech-
ology, Birmingham, AL), rabbit anti-mouse Ig-FITC (Da-
opatts AB), rabbit anti-rat absorbed against mouse Ig
Dakopatts, Glustrup, Denmark), and Texas red-conju-
ated swine anti-rabbit Ig (Dakopatts).
mmunofluorescence
The cells were deposited on slides with cytospin and
ixed in 220°C acetone–methanol (1:1). The slides were
xposed for 20 min to 10% normal goat serum for block-
ng and thereafter incubated with the first antibody, A-22
nti-CBP (1:400) or N-15 anti-p300 (1:100), for 60 min at
oom temperature. This was followed by 30 min incuba-
ion with swine anti-rabbit IgG-FITC (1:40). Nuclear DNA
as stained with 40 ng/ml of Hoechst 33258 (Molecular
robes, Europe BV). The stained cells were mounted
ith 70% glycerol, 2.5% DABCO (Sigma), pH 8.5, in PBS.
Double immunofluorescence stainings for CBP or
300 and EBNA5 were carried out in the following order:
0% normal goat serum, A-22 anti-CBP antibody (1:400)
r N-15 anti-p300 (1:100), swine anti-rabbit IgG-FITC (1:
0), 10% normal mouse serum, JF186 biotinylated anti-
BNA-5 (1:30), and Texas red-conjugated streptavidin
1:250, Vector Laboratories, Burlingame, CA). Double im-
unofluorescence for CBP or p300 and EBNA2 was
arried out in the following order: 10% normal goat se-
um, A-22 anti-CBP antibody (1:400) or N-15 anti-p300
1:100), swine anti-rabbit IgG-FITC (1:40), PE-2 anti
BNA-2 (1:20), goat anti-mouse IgG-biotin (1:100), and
exas red-conjugated streptavidin (1:250).
Double staining for PML and CBP was carried out in
he following order: 10% normal goat serum, A-22 anti-
BP antibody (1:400), swine anti-rabbit IgG-FITC (1:40),
G-M3 anti-PML (1:50), goat anti-mouse IgG-biotin (1:
00), and Texas red-conjugated streptavidin (1:250). Dou-
le PML and EBNA5 was carried out in the following
rder: 10% normal rabbit serum, PG-M3 anti-PML (1:50),
nd rabbit anti-mouse Ig-FITC (1:20), 10% normal mouse
erum, JF186 biotinylated anti-EBNA-5 (1:30), and Texas
ed-conjugated streptavidin (1:250).Double staining for EBNA-2 and RBP-Jk was carried
ut as follows: First, the EBNA-2 specific antibody PE-2
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281INTRANUCLEAR LOCALIZATION OF CBP/p300, EBNA-2, AND EBNA-5(1:20) was used. This mouse Ig was detected with goat
anti-mouse IgG–biotin (1:100). Excess anti-mouse Ig re-
activities were eliminated by 10% mouse serum. The
cells were then incubated with rat monoclonal anti-
RBP-Jk T6719 (1:50)/10% mouse sera overnight at 4°C.
The rat Ig was probed with rabbit anti-rat absorbed
against mouse Ig (1:30). Then biotin and rabbit Ig were
detected by the mixture of FITC-conjugated streptavidin
(1:250, Pharmingen, San Diego, CA) and Texas red-con-
jugated swine anti-rabbit Ig (1:30).
Image analysis
The slides were examined in a Leitz DM RB micro-
scope. Composite filter cubes were used for the FITC,
Texas red, and Hoechst 33258, respectively. The images
were captured with a HAMAMATSU dual mode cold-CCD
camera (C4880) as 8-bit uncompressed TIFF files. They
were analyzed using Image-Pro Plus (Media Cybernet-
ics) and Adobe PhotoShop 3.0 (Adobe Systems Inc.) as
previously described (Teramoto et al., 2000). Some of the
mages (Fig. 5) were captured on a 3D microscope using
he ST-lFH-bind program that is a novel derivative of the
reviously published TROOPER3 and STEREOTROOPER
ith correlation for shine through (Holmvall and Sze´kely,
999). This program creates a reconstituted image from
series of optical sections (at 0.2 mm distance) taken by
old-CCD camera with wide-field illumination. The sec-
ions were deblurred using the nearest neighbor algo-
ithm.
mmunoblotting
The cells were lysed in loading buffer. Aliqouts corre-
ponding to 2.5 3 105 cells were electrophoresed in 5%
DS–PAGE gel and transferred to polyvinylidene difluo-
ide (PVDF) membranes at 75V for 2 h. After blocking the
embranes by exposure to 7.5% nonfat dried milk in
BS–Tween 20 for 1 h, they were incubated with the
nti-CBP/p300 antibody overnight at 4°C. The blots were
hen incubated with horseradish peroxidase-conjugated
onkey anti-rabbit Ig antibody (Amersham, Arlington
eights, IL, 1:2500 dilution) and detected with ECL1Plus
etection reagent (Amersham).
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